Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis.

@article{Mesk2012PeripheralBG,
  title={Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis.},
  author={Bertalan Mesk{\'o} and Szil{\'a}rd P{\'o}liska and Szilvia Szamosi and Zolt{\'a}n Szekanecz and J{\'a}nos Podani and Csaba V{\'a}radi and Andr{\'a}s Guttman and L{\'a}szl{\'o} Nagy},
  journal={The Journal of rheumatology},
  year={2012},
  volume={39 5},
  pages={
          916-28
        }
}
OBJECTIVE Tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, has recently been approved as a biological therapy for rheumatoid arthritis (RA) and other diseases. It is not known if there are characteristic changes in gene expression and immunoglobulin G glycosylation during therapy or in response to treatment. METHODS Global gene expression profiles from peripheral blood mononuclear cells of 13 patients with RA and active disease at Week 0 (baseline) and Week 4… CONTINUE READING
BETA

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Similar Papers

Loading similar papers…